Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).

doi:10.1016/j.annonc.2022.02.225

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jun 2022

Janning M, Süptitz J, Albers-Leischner C, Delpy P, Tufman A, Velthaus-Rusik J-L, Reck M, Jung A, Kauffmann-Guerrero D, Bonzheim I, Brändlein S, Hummel H-D, Wiesweg M, Schildhaus H-U, Stratmann J A, Sebastian M, Alt J, Buth J, Esposito I, Berger J, Tögel L, Saalfeld F C, Wermke M, Merkelbach-Bruse S, Hillmer A M, Klauschen F, Bokemeyer C, Buettner R, Wolf J, Loges S

Abstract excerpt

BACKGROUND: Atypical EGFR mutations occur in 10%-30% of non-small-cell lung cancer (NSCLC) patients with EGFR mutations and their sensitivity to classical epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) is highly heterogeneous. Patients harboring one group of uncommon, recurrent EGFR mutations (G719X, S768I, L861Q) respond to EGFR-TKI. Exon 20 insertions are mostly insensitive to EGFR-TKI...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Cancer Treatments and Mutations

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 35263633
DOI: 10.1016/j.annonc.2022.02.225

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).PMID 35263633Read ↗

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical ScenarioSemantic proximity Read ↗

Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.Semantic proximity Read ↗

Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical NeedSemantic proximity Read ↗

Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review.Semantic proximity Read ↗

The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal.Semantic proximity Read ↗

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysisSemantic proximity Read ↗

Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need.Semantic proximity Read ↗

Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC.Semantic proximity Read ↗

Uncommon EGFR mutations in advanced non-small cell lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor (EGFR) atypical mutations in non-small-cell lung cancer (NSCLC): 'Where the streets have no name'.Semantic proximity Read ↗

Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatmentSemantic proximity Read ↗

First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution's clinical practice experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.